文献速递脑血管病

达比加群逆转后静脉溶栓治疗急性缺血性卒中:一项全国登记研究及荟萃分析

Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke: A National Registry-Based Study and Meta-Analysis.
PubMed 文献 · Neurology · 2024-09-10

该全国登记研究及荟萃分析纳入13个队列和1个病例系列共553例急性缺血性卒中患者,评估达比加群经依达赛珠单抗逆转后静脉溶栓的安全性和有效性。汇总症状性颅内出血率为4%,3个月死亡率为18%,良好功能结局(mRS 0-2)为70%,与未用达比加群患者相比症状性颅内出血、任何颅内出血和3个月死亡率无显著差异,但良好功能结局可能性更高(RR 1.35)。作者认为观察性研究中该做法似乎安全有效,但需随机对照试验提供有力证据。

要点

  • 达比加群逆转后静脉溶栓的汇总症状性颅内出血率为4%(95% CI 1-9)。
  • 与未用达比加群者相比,症状性颅内出血风险无显著差异(RR 1.86;95% CI 0.91-3.80)。
  • 达比加群逆转后静脉溶栓与3个月良好功能结局可能性更高相关(RR 1.35;95% CI 1.11-1.65)。

核心结论

  • 在患者数量有限的观察性研究中,达比加群经依达赛珠单抗逆转后静脉溶栓治疗急性缺血性卒中似乎安全有效。
  • 需要随机对照临床试验为该特定急性缺血性卒中亚组静脉溶栓的安全性和有效性提供有力证据。

研究设计与样本

  • 全国登记研究评估该特定亚组静脉溶栓的安全性和有效性。
  • 系统综述和荟萃分析纳入队列研究和病例系列,共13个队列(包括本 nationwide 登记队列)和1个病例系列,合计553例急性缺血性卒中患者(平均年龄75岁;男性65%;基线NIH卒中量表评分中位数11分)。

主要发现

  • 静脉溶栓后症状性颅内出血汇总率为4%(95% CI 1-9;I²=26%)。
  • 任何颅内出血汇总率为10%(95% CI 5-16;I²=24%),3个月死亡率汇总率为18%(95% CI 10-27;I²=0%)。
  • 3个月极好功能结局(mRS 0-1)汇总率为56%(95% CI 27-83;I²=69%),良好功能结局(mRS 0-2)汇总率为70%(95% CI 57-81;I²=40%)。
  • 接受依达赛珠单抗与未接受者相比,症状性颅内出血风险(RR 1.86;95% CI 0.91-3.80;I²=0%)、任何颅内出血风险(RR 1.76;95% CI 0.99-3.11;I²=8%)和3个月死亡率(RR 1.50;95% CI 0.91-2.48;I²=0%)无显著差异。
  • 依达赛珠单抗给药与达到3个月良好功能结局的可能性更高相关(RR 1.35;95% CI 1.11-1.65;I²=27%)。

临床怎么用

  • 作者认为,在观察性研究中,达比加群经依达赛珠单抗逆转后静脉溶栓治疗急性缺血性卒中似乎安全有效。
  • 作者指出需要随机对照临床试验为该特定急性缺血性卒中亚组静脉溶栓的安全性和有效性提供有力证据。

局限性

  • 观察性研究中患者数量有限。
  • 需要随机对照临床试验提供有力证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Limited data exist on the safety of IV thrombolysis (IVT) for acute ischemic stroke (AIS) after dabigatran reversal with idarucizumab. We sought to evaluate the safety and efficacy of idarucizumab pretreatment in patients with AIS receiving IVT. METHODS: A national registry-based study evaluated the safety and efficacy of IVT in this specific subgroup. We also conducted a systematic review and meta-analysis of cohort studies and case series, aiming to document the pooled rates of (1) symptomatic intracranial hemorrhage (sICH), (2) any intracranial hemorrhage, (3) 3-month mortality, and (4) the proportion of excellent (modified Rankin Scale [mRS] scores 0-1) and (5) good (mRS scores 0-2) functional outcome at 3 months among patients with AIS, who received IVT after dabigatran reversal with idarucizumab. Moreover, we sought to compare these outcomes between IVT-treated patients after dabigatran reversal with idarucizumab and IVT-treated patients without dabigatran pretreatment. RESULTS: Thirteen cohorts including our nation-wide registry-based cohort and 1 case series comprising 553 patients with AIS (mean age: 75 years; male sex: 65%; median baseline NIH Stroke Scale score: 11 points) receiving idarucizumab before IVT were included in this meta-analysis. The pooled rate of sICH after IVT after idarucizumab administration was 4% (95% CI 1-9; I2 = 26%), while the pooled rates of any intracranial hemorrhage and 3-month mortality were 10% (95% CI 5-16; I2 = 24%) and 18% (95% CI 10-27; I2 = 0%), respectively. The pooled rates of excellent and good functional outcomes at 3 months were 56% (95% CI 27-83; I2 = 69%) and 70% (95% CI 57-81; I2 = 40%), respectively. The risk of sICH (risk ratio [RR] 1.86; 95% CI 0.91-3.80; I2 = 0%), any intracranial hemorrhage (RR 1.76; 95% CI 0.99-3.11; I2 = 8%), and 3-month mortality (RR 1.50; 95% CI 0.91-2.48; I2 = 0%) did not differ between patients with AIS receiving IVT with and without idarucizumab. Moreover, idarucizumab administration was associated with higher likelihood of achieving a 3-month good functional outcome (RR 1.35; 95% CI 1.11-1.65; I2 = 27%). DISCUSSION: IVT for AIS after dabigatran reversal with idarucizumab seems to be safe and effective in observational studies with limited number of patients. Randomized-controlled clinical trials are warranted to provide robust evidence on the safety and efficacy of IVT in this specific AIS subgroup.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Theodorou A, Melanis K, Bakola E, et al. Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke: A National Registry-Based Study and Meta-Analysis. Neurology. 2024. PMID: 39255429. doi:10.1212/WNL.0000000000209862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。